TREATMENT PATTERNS OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) IN US COMMERCIAL PLANS

被引：0
|
作者：
Jiang, S. [1 ]
Hill, K. [2 ]
Varghese, D. [1 ]
Waldeck, R. [2 ]
Botteman, M. [1 ]
机构：
[1] Pharmerit Int, Bethesda, MD USA
[2] Celldex Therapeut, Hampton, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN221
引用
收藏
页码：A127 / A127
页数：1
相关论文
共 50 条
  • [31] Atezolizumab for metastatic triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (10): : E519 - E519
  • [32] Iniparib in Metastatic Triple-Negative Breast Cancer
    Domagala, Pawel
    Lubinski, Jan
    Domagala, Wenancjusz
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18): : 1780 - 1780
  • [33] Physician treatment preferences for metastatic triple negative breast cancer (mTNBC) in an era of immunotherapy.
    Gajra, Ajeet
    Wojtynek, Jeffrey
    Dokubo, Igoni
    Jeune-Smith, Yolaine
    Kish, Jonathan
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Petru, Edgar
    Egle, Daniel
    Gnant, Michael
    Balic, Marija
    Sliwa, Thamer
    Singer, Christian
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (11-12) : 347 - 361
  • [35] Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review
    Madsen, Anna Martha Hammershoi
    Eefsen, Rikke Helene Lovendahl
    Nielsen, Dorte
    Kumler, Iben
    BREAST JOURNAL, 2024, 2024
  • [36] Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020
    Azim, Hamdy A.
    Ghosn, Marwan
    Oualla, Karima
    Kassem, Loay
    BREAST JOURNAL, 2020, 26 (01): : 69 - 80
  • [37] Treatment patterns and associated adverse events among patients with metastatic triple-negative breast cancer.
    Kaklamani, Virginia G.
    Schultz, Neil M.
    Irwin, Debra E.
    Fulcher, Nicole
    Noxon, Virginia
    Wu, Jun
    Pandya, Bhavik J.
    Kim, Ruth
    Barley, Arie
    Flanders, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC)
    Keenan, Tanya E.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    Kochupurakkal, Bose
    Guerriero, Jennifer L.
    Tahara, Rie K.
    Winship, Grace
    Osmani, Wafa
    Andrews, Chelsea
    Conway, Jake R.
    He, Meng X.
    Pastorello, Ricardo
    Tracy, Adam
    Godin, Robert E.
    Overmoyer, Beth A.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Shapiro, Geoffrey I.
    Van Allen, Eliezer M.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [39] Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis.
    Kuderer, Nicole Maria
    Varghese, Della
    Hill, Kala
    Lyman, Gary H.
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC)
    Qattan, Amal
    Al-Tweigeri, Taher
    Suleman, Kausar
    Alkhayal, Wafa
    Tulbah, Asma
    CANCERS, 2024, 16 (17)
12345